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Abstract 
 
This thesis deals with how companies in the pharmaceutical industry are allocating the 
development of innovations and what benefits there are by implementing Open Innovation 
strategies. Two principal companies, AstraZeneca and Eli Lilly and Company, have been 
investigated. This thesis aims at finding answers to how Open Innovation is performed within 
AstraZeneca and Eli Lilly and Company, what incentives there are for these companies to 
engage in Open Innovation and to investigate whether there are complications considering 
Intellectual Property (IP) for these companies when it comes to Open Innovation.  
 
The two pharmaceutical companies are both highly depending on innovations and have 
approached different strategies towards Open Innovation and these strategies are examined in 
the case study of this thesis. It can be concluded that the pharmaceutical industry is changing 
and that pharmaceutical companies need to find new approaches of innovating in order to stay 
competitive, something that both AstraZeneca and Eli Lilly and Company are looking into. 
This thesis further concludes that there are different interpretations of Open Innovation in the 
pharmaceutical industry; however, the development of innovation strategies indicates that 
openness is imperative in order to stay competitive.  
 
Key words: Open innovation, innovation, pharmaceutical industry, intellectual property, 
crowdsourcing, AstraZeneca, Eli Lilly  
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1. Introduction 
The first chapter presents the background and purpose of this thesis. The research questions 
are presented as well as the used limitations. This chapter also illustrates the outline of all 
chapters of the thesis in order to provide the reader with an overview. 
1.1 Background 
Innovation is an extremely important tool for companies in different industries around the 
world and Baumol (2002) points out that almost all economic growth in the last centuries can 
be traced back to innovation. Innovation has a number of definitions and one of the most 
influential actors in this area, Peter Drucker, defines innovation as a “change that creates a 
new dimension of performance” (Hesselbein, Goldsmith & Somerville, 2002). 
 
Companies need research and development (R&D) to develop new products in order to stay 
ahead of competitors. Traditionally, R&D has been conducted internally within companies 
that have been careful not to display any knowledge or company secrets to competitors 
(although, there have been examples of collaborations in industries that required technology 
transactions in the birth of that industry (e.g. chemicals), these were very few exceptions a 
long time ago (Lichtenthaler, 2012)). In recent times companies have started to rethink, and 
have come to an understanding that themselves only employ a small fraction of the scientists 
in their specific area, and that they can gain from collaborating with other companies with 
similar activities. This all falls in place with the use and realization of the phrase “not all the 
best people work for you” (Chesbrough, 2003).  
 
Henry Chesbrough (2003) coined the term “Open Innovation” and explains how companies 
open up and start to collaborate with each other in order to create and profit from technology. 
There are a number of examples in the IT, electronics and the pharmaceutical industry 
(Chesbrough, 2003; Hunter & Stephens, 2010; Sloane, 2011) among others and Open 
Innovation is an upcoming, up-to-date and different way of dealing with new product 
development. 
 
The topic Open Innovation also raises issues that are complex to explain without further 
research and understanding. It is mainly the problem of protecting IP that comes to mind 
when companies share information and technology. Along with an increasing number of 
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collaborations, the complexity of conducting innovations increases as well and many 
companies still claim that they do better without outside intervention (Remneland, 2010). In 
this thesis the meaning of Open Innovation will be clarified and the role of Open Innovation 
in the pharmaceutical industry closely investigated. 
1.2 Problem discussion and purpose 
Industries that are knowledge intense are particularly interesting to observe when it comes to 
Open Innovation since Open Innovation allows companies to spread risks and reduce lead 
times and thus increase their competitiveness. Open Innovation has evolved in the last decade 
and has become increasingly common and it is interesting to examine the reasons for this 
occurrence. Companies in the pharmaceutical industry rely on innovations in order to stay 
profitable and ahead of competitors, and this thesis aims to investigate whether Open 
Innovation is beneficial for companies in the pharmaceutical industry or if sharing knowledge 
makes these companies more vulnerable to competitors.  
 
This thesis aims to provide a view of Open Innovation in general and how it is used in the 
pharmaceutical industry in particular, with specific focus on the two pharmaceutical 
companies AstraZeneca and Eli Lilly and Company (hereafter named Lilly). To find answers 
to these inquiries, case studies on how the companies perceive and adopt Open Innovation 
will be conducted. In addition, information about the pharmaceutical industry and drug 
development will be used to support the problem discussion.  
 
Open Innovation is a topic with many different definitions depending on the background of 
the spectator. As a consequence, a conceptual framework is necessary and will be presented in 
order to clarify the definition of Open Innovation in this thesis and why it should, or should 
not, be considered as a strategy by companies and investors. Open Innovation can be 
conducted in several ways and a number of issues such as protection of IP, collaboration 
contracts and the Open Innovation process will be explained and examined in this thesis.  
 
In order to investigate the problem, the following research questions have been set out to 
narrow down the approach: 
 
1. How is Open Innovation performed within AstraZeneca and Lilly?  
2. What incentives do these companies have to engage in Open Innovation?  
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3. How do these companies handle issues with IP rights when engaging in Open Innovation 
strategies?  
1.3 Limitations 
The subject of innovation is extremely vast; therefore this thesis will be focusing on one 
segment; Open Innovation within the pharmaceutical industry. The limitation and focus on the 
pharmaceutical industry is mainly due to the importance of innovation within this industry 
and the fact that R&D of drugs is expensive and need new approaches. This thesis is limited 
to what Open Innovation means for the pharmaceutical companies AstraZeneca and Lilly 
based on the fact that shorter product lifecycles force companies to increase investments in 
innovations in order to stay competitive. Open Innovation has different interpretations in 
different companies and a conceptual framework will be presented in the theoretical 
framework order to clarify the meaning. 
 
The case study of this thesis is limited to the exploratory study of AstraZeneca and Lilly, and 
how these companies relate to Open Innovation. These two companies are among the biggest 
in the pharmaceutical industry and the findings can provide an indication on how Open 
Innovation is perceived within the industry as a whole. Additional information from the 
industry serves as support to the chosen companies and the analysis. 
1.4 Thesis outline 
The first section provides a short introduction to the subject that leads up to the problem 
discussion and purpose. It is important to create a well developed and detailed background 
section since it is an essential part of this thesis and will lead up to the theoretical framework. 
The second section describes the use of method and how the thesis is conducted, as well as 
arguments for the choice of method and method criticism. The third section covers the 
theoretical framework on which the empirical study will be based. The most relevant and 
influential theories considering Open Innovation will be presented in the theoretical 
framework. The fourth section will be divided into three parts; the first will explain the nature 
of the pharmaceutical industry and drug development, the second part will cover the case of 
AstraZeneca and the third part illustrates the case of Lilly. The fifth section will provide a 
thorough analysis of the empirical studies performed in the fourth section and be 
complemented with a discussion considering the future of the pharmaceutical industry 
regarding innovations in general and Open Innovation in particular. In the sixth section, the 
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conclusion of the analysis will be presented and connected with the research question 
presented in the opening of this thesis. The sixth section will be wrapped up by presenting the 
authors’ recommendations for future research within the same field. 
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2. Method 
The second chapter illustrates the methods used in order to conduct this thesis. In addition, 
arguments for why the authors have found these methods best suited will be explained as well 
as alternative methods and method criticism. 
2.1 Research design 
Innovation is important for any knowledge intense company, and the globalized world today 
increases competition, which further motivates innovation. The aim of this thesis is to 
visualize the Open Innovation process in general and explain and clarify why Open 
Innovation has developed with a focus on the pharmaceutical industry by explaining these 
forces. In order to execute the empirical research on the pharmaceutical companies 
AstraZeneca and Lilly, an exploratory approach by using a qualitative research method has 
been chosen. A qualitative research study is believed to be better suited than a quantitative 
method since a deeper understanding of the examined companies’ point of view of Open 
Innovation is the primary purpose of this thesis. A quantitative method is normally used in 
order to collect statistical data and conduct statistical analyses. The motives for the choice of 
method lie within the nature of the research questions; why the strategy and phenomenon of 
Open Innovation occurs and from a theoretical, motivational point of view that connect the 
results back to the empirical results. 
 
This research consists primarily of literature of different characteristics such as textbooks, 
articles and dissertations. Furthermore, case studies of AstraZeneca and Lilly will be 
conducted. The aim of using this approach is to gain a thorough understanding of the subject 
and of how these companies relate to Open Innovation.   
2.2 Research approach 
The method explains the scientific base and the execution of the work of this thesis. There are 
three different methodological approaches to apply in order to execute a thesis. A deductive 
approach implies that theories are used as the starting point for the research study and used by 
the researcher in order to reason a hypothesis by logic based on the theoretical framework. In 
turn, execute an empirical study based on these facts. Critique for applying a deductive 
method approach is that it is challenging for the researcher not to find data and information 
that confirms the already outworked and stated theory (Jacobsen, 2002). The results of the 
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empirical study might thus be angled in order to confirm existing theory. The contrasting 
methodological approach to deductive is inductive which means that theory and conclusions 
are developed through empirical research and data collection; hence the role of the empirical 
study plays a significant role while using the inductive method approach. The abductive 
approach is a mix of the two previous in the way that much emphasis is put into the existing 
theoretical framework, but the empirical study is the tool in order to revise what has been 
stated as theory (Eriksson & Kovalainen, 2008).  
 
This thesis is based on an inductive, exploratory approach due to the fact that the conclusions 
are based on the empirical observations of AstraZeneca and Lilly. Theories and analyses that 
have been developed considering innovations and the motives behind innovations will be 
included as well as the role of globalization on competition, and the definition and 
development of the Open Innovation paradigm. Moreover, it is possible to conduct a research 
with either a descriptive or interpretational approach, and it is found that the descriptive 
approach is better suited as the purpose of this thesis is to understand and explain Open 
Innovation in the pharmaceutical industry. 
2.3 The case studies 
Case studies should be executed if the research question tackles complex managerial and/or 
organizational business concerns since these subjects need to bee examined from more than 
one perspective and thus can be difficult to investigate while using a quantitative research 
approach (Eriksson & Kovalainen, 2008). This thesis aims at illustrating the subject of Open 
Innovation as well as controlling whether existing theory on the subject is representative of 
the point of view of concerned businesses. With a research question that “deals with 
operational links needing to be traced over time”, a case study of qualitative nature is desired 
(Yin, 2009). 
 
In this thesis case studies have been performed in order to investigate what Open Innovation 
means for knowledge intense companies in the pharmaceutical industry with the purpose to 
confirm or dismiss the theories in the theoretical framework. Two large pharmaceutical 
companies, AstraZeneca and Lilly, have been chosen for this purpose. AstraZeneca was 
selected because it is a big company with roots in Sweden where it employs 7,600 people 
(AstraZeneca, 2012a). Lilly was selected due to the fact that is a prominent company within 
Open Innovation (Chesbrough & Garman, 2009). The two companies are among the “Big 
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Pharmas”, which refer to the big, globally well-established and capital strong pharmaceutical 
companies, and are thus, to a certain extent, considered to represent the industry. Case studies 
have been performed by thorough interviews with informed and influential personnel at 
AstraZeneca, as well as literature research of both companies. Lilly has an apparent approach 
to Open Innovation and information was found with minor difficulties. Conversely, 
AstraZeneca’s approach is less clear and required further explanations and information, which 
is the reason why interviews were held with AstraZeneca but not with Lilly. 
2.4 Data collection 
Primarily this thesis has been conducted on a basis of literature in the form of textbooks, 
research papers, documentations and dissertations from the field of both innovation and Open 
Innovation and articles considering pharmaceutical companies and the importance of 
openness in this industry. These readings have been the foundation for this thesis, and 
interviews with Anders Ekblom and Mats Sundgren, personnel in managerial positions at 
AstraZeneca in Södertälje and Mölndal, Sweden have assembled the data for the qualitative, 
empirical study. This information has made it possible to connect real-life situations 
considering strategy in the pharmaceutical industry with literature in the same field. The 
purpose with the interviews has been to investigate the correspondence and reliability of the 
theory on this subject.  
 
In order for the authors to gain a better understanding of how Open Innovation in the 
pharmaceutical industry is adopted, interviews with Björn Remneland, and Alexander Styhre, 
researchers and professors at the School of Business, Economics and Law at the University of 
Gothenburg, have been held. 
 
In addition, data has been collected through thorough research of Lilly and its different 
innovation processes. 
2.5 Method criticism 
Any chosen method of approach comes with certain disadvantages. The same goes for the 
chosen practice of a qualitative case study when scrutinizing the subject of Open Innovation. 
When using a qualitative approach the perception and point of view of a limited number of 
actors on the market is reached and this in turn will provide a somewhat non-faceted 
observation to base the analysis on. The inductive approach can be criticized since the 
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observed empirical material is limited (here the two companies) and thus hard to interpret as 
representative. However, the conviction is that the method chosen is the most appropriate one 
for this thesis and its purpose. The conclusion and research of this thesis is based on the 
interviewees’ perception regarding Open Innovation and in turn by the authors and compared 
to existing literature on the subject in question. The conceptual framework is thus an 
important element since the interpretation of the term Open Innovation might differ 
depending on the interviewee. 
2.6 Reliability and validity 
A reliable thesis implies that the results that emerge from the research study would be the 
same if the same research were to be done by another researcher, i.e. replicable (Yin, 2009). 
For this particular thesis that treats an up to date and debated topic, the importance of time 
and place must be emphasized. This research is assumed to be reliable to a great extent due to 
the thorough development of the theoretical framework and later on the direct connection 
between theory and empirics. As the approach of this thesis is descriptive, it is possible to 
consider the level of reliability of the analysis as relatively high, since it should be possible to 
replicate the analysis if the same empirical material was used. However, the world of 
pharmaceuticals today stands before great change (Hedner, 2011), which means that even if it 
is possible to replicate the analysis, a future empirical study on the same companies would 
probably not generate the same answers. Therefore it might not be appropriate to discuss the 
reliability of the results of this research other than the connections made between the stated 
theory and the developed analysis.    
 
The validity of a study determines how well the research questions have been answered and 
how well the tools used in the research measures what they are intended to measure (Cohen, 
Manion & Morrison, 2007). Which means that if the study achieves to answer what it was set 
out to answer. In order to reach as high validity of this thesis and of the case study as possible, 
an explanation of the phenomenon and definition of Open Innovation and other related 
theories in the theoretical framework will be presented. Throughout the development of this 
thesis the research questions and the purpose have been continuously considered in order to 
maintain a common thread from start to finish. 
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3. Theoretical and Conceptual Framework 
The third chapter explains the theories and models used in order to understand Open 
Innovation. A conceptual framework is also presented in order to give the reader a clear 
definition of the authors’ perception of Open Innovation, and the critique against the novelty 
of Open Innovation will be introduced. Additionally, the importance of IP rights will round off 
the theoretical framework. 
3.1 Conceptual framework 
The definition of Open Innovation can be vague and difficult to grasp, therefore it is 
important that this thesis early defines how the term Open Innovation will be handled in the 
following sections. Open Innovation should not be confused with “Free Innovation”, which 
means that R&D and investments will be available in the open space and thus free for anyone 
to employ, therefore many researchers on the subject (e.g. O’Connell, 2011) distinguish the 
terms Open Innovation and External Innovation in order not to confuse the word “open” with 
“free”. However, this thesis will employ the terminology “Open Innovation” as coined by 
Henry Chesbrough (2003), thus Open Innovation refers to two principal implications; 
1. To acknowledge and look for extern knowledge, skills, innovations and talents. 
2. To be willing to open up the, until recently, closed bank of IP rights within a company 
and sell or license out IP rights that the company is not using. 
3.2 The novelty of Open Innovation 
The phenomenon of Open Innovation is stated to be novelty and to differ from the traditional 
attitude and approach towards innovations (the differences between the traditional, closed 
model for innovation and the new, open model are explained below). However, many 
researchers in the field of strategy and innovation agree on one thing; the idea of looking for 
beneficial external ideas and proficiency in order to facilitate the internal innovation process 
is neither new nor ice breaking (Kielstra, 2011; Remneland, 2010). Companies have been 
collaborating, sharing IP rights by contracting and licensing as well as recruiting and working 
close with academia for a long time. Especially academic research has been of great 
importance for the development of many highly technological products, nonetheless for drug 
discovery and innovations. Universities have the potentials to conduct R&D of new molecular 
entities that are needed to develop new drugs. However, they do not have the finances neither 
to further develop the drug, nor to bring the new product to the market. This is where big 
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pharmaceutical companies can contribute. These companies have the finances and the 
marketing and development proficiencies to invest in the development of new molecular 
entities and bring them to the market, something that universities normally lack of. These are 
all activities that are neither foreign nor new by content to any actor in highly innovative 
industries such as pharmaceuticals. Therefore there is critique to address the phenomenon of 
Open Innovation coined by Chesbrough (2003), and it is legitimate to question if Chesbrough 
pointed out and termed something that has been done for decades, and if the novelty of Open 
Innovation is the terminology rather than the function. Hullmann (2000) discusses the 
collaborations of pharmaceutical companies and states that external knowledge has always 
been seen as a supplement to own research and that scientific research in universities has 
created a source of information and innovations with lower costs and risks for the 
pharmaceutical companies. However, Chesbrough is not to be entirely criticized since there is 
a new need for how to proceed with innovations that differs from earlier needs. This has to do 
with shorter product lifecycles, increased competition and globalization, thus the novelty of 
the Open Innovation paradigm lies in the necessity of acquiring ideas and innovations to a 
lower budget as well as the role of trade of IP rights. 
3.3 The product lifecycle 
The life of a new product today is becoming shorter and shorter, consumer needs are 
becoming more and more complex and diverse, and these are factors that indicate higher 
pressure than ever before on innovators and innovating companies (Christensen, 2011). It is 
important to understand the life of a product in order to understand the importance of 
innovation, may it be radical or incremental. The product lifecycle in an existing market is a 
theory explained mostly by marketing literature. The theory explains that uncertainties of a 
product, and thus uncertainties considering the profits of this product are deeply interlinked 
with the market in question. There are five stages in the product lifecycle that represents the 
phases a product goes through, and each phase plays a different role considering the 
profitability of a product (Figure 3.1). 1) The first stage is the development stage where the 
product is being developed and tested to get ready to be launched on the market. 2) The 
second stage is the introduction stage which is, as understood, the phase that starts when a 
product is introduced to a new market. The characteristics of the introduction stage imply low 
sales and thus low (or even negative) profits, high costs per customer and few competitors. 3) 
The next stage is the growth stage where costs per customer start to decrease, profits are 
increasing along with quickly increased sales. 4) Thereafter comes a product’s maturity stage 
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where sales and profit peak and the number of competitors is stable. 5) The last stage is when 
a product is in decline, this phase is characterized by weaker sales and increasing costs per 
customer (Baines, Fill & Page, 2008; Kotler, Keller, & Brady, 2009). For a company to 
maximize sales it is important to make sure that a product does not enter the decline phase. 
Therefore the maturity stage needs to be prolonged either through new innovations, adapted 
products or by finding new target markets or segments (Afuah, 2003). 
The explanation of the product lifecycle is necessary since it allows us to understand the 
meaning and importance of innovations. Innovations are interlinked with profitability when a 
prolonged maturity phase is realized, and today’s competitiveness and increased power of the 
consumer makes innovations crucial for any company that wants to maintain a high profit 
margin. 
 
 
Figure 3.1 The Product Lifecycle (Baines, Fill & Page, 2008) elaborated by the authors 
 
3.4 Traditional vs. Open Innovation 
In this section the different frameworks of innovation will be outlined. In order to understand 
how Open Innovation has emerged, the traditional way of innovating and the reason why it 
has been considered to be the best way of conducting R&D will be presented. A clarification 
of the different approaches of Open Innovation will be described as well as the different 
theories within these approaches. 
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3.4.1 Closed Innovation 
The traditional way of creating innovations has been to innovate and develop products in-
house, i.e. Closed Innovation (Chesbrough, 2003). Companies have been keen on keeping 
knowledge and talent within company walls and on making sure that innovations, intellectual 
capital and IP are created and retained within the company. Benefits from implementing a 
Closed Innovation model are control over the innovation process from start to finish as well as 
creation of IP rights (Motzek, 2007). In addition, the perception that “successful innovation 
requires control” motivated companies to conduct all innovations internally to be sure that 
other parties’ lack of quality or capabilities would not affect internal operations (Chesbrough, 
2003). Companies also had the attitude that “all the smart people work for me” (Chesbrough, 
2003; Chesbrough, Vanhaverbeke & West, 2006). Chesbrough (2003) further mentions a 
number of implicit rules that companies followed such as hiring the best talents, that the first 
to innovate will be the first in the market and gain large market shares, and that leading the 
R&D within an industry will produce the most successful innovations. All of this led to a 
virtuous circle; fundamental breakthroughs brought new products, which boosted sales and 
profits, which led to increased investment in R&D and then on to new fundamental 
breakthroughs. 
 
The Closed Paradigm shows the flow of innovations from start to finish where resources are 
put into an innovation funnel (figure 3.2). The R&D take place within the boundaries of the 
firm and no external parties are involved (Grönlund, Rönnberg Sjödin & Frishammar, 2010). 
 
This way of relying on a company’s own capacity is still, to a great extent, implemented in 
many companies. However, a shift of this trend can be seen towards alternative ways of 
attaining knowledge and access to external talents, and it is obvious that not all the best talents 
in the industry could possibly work for the same company. In the late 20th century, a number 
of changes in the business environment made companies rethink their R&D processes 
(Chesbrough, 2003). It became harder to retain knowledge within the firm due to growing 
mobility among skilled people who brought their experience along to other companies. The 
increase in venture capital was another factor that had an impact. Venture capital was used to 
create new companies that specialized in commercialising external research, and hence new 
competitors emerged. On top of this, the products’ lifetime decreased, and as new competitors 
arose from other regions in the world it became more important to come up with new 
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technology and ideas faster. All of this led to a drive to search for knowledge and talent 
outside company walls. 
 
 
Figure 3.2 The Closed Innovation Paradigm (Chesbrough, 2003) elaborated by the authors 
3.4.2 Open Innovation 
The above-explained changes in the business environment gave inventors an alternative 
option after a fundamental breakthrough; to form a new company to develop the innovation 
with help from venture capital. If the innovation became successful, it was sold off; hence it 
did not generally reinvest its profit and the virtuous circle was broken (Chesbrough, 2003). 
Where this took place, a new framework was needed due to the lack of funding for R&D, and 
this is where the Open Innovation Paradigm is introduced. 
 
Henry Chesbrough’s (2003) definition of Open Innovation is:  
 
“Open Innovation is a paradigm that assumes that firms can and should 
 use external ideas as well as internal ideas, and internal and external paths to market, as 
they look to advance their technology.”  
 
Open Innovation can be performed in a large number of ways, however, the general idea is to 
use external sources and thus remove the boundaries of the firm, making information and 
knowledge flow in and out of the company (figure 3.3). In the end, projects can be spun out of 
the company through start ups of new firms with employees from the own company in order 
to target new markets (Chesbrough, 2003). Other ways to handle potentially useful 
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innovations that are not being used in the company’s activities could be through licensing, 
collaborations with other firms or through starting up joint ventures (Hedner, 2012). A 
company also has to realize that internal research may fail and that other parties may come up 
with better solutions. Hence, companies have to be ready to acquire innovations or knowledge 
(e.g. patents) and continue to develop these in-house (Hedner, Thornblad, Remneland & 
Klofsten, 2011). Companies should also be prepared to sell off IP rights such as patents in 
order to make money from underused assets.  
 
 
Figure 3.3 The Open Innovation Paradigm (Chesbrough, 2003) elaborated by authors 
 
Gassmann and Enkel (2004) have identified three core Open Innovation processes. The 
outside-in process, the inside-out process and the coupled process strategy. The outside-in 
process enriches a company’s own expertise by integrating external parties in the innovation 
process. Conversely, the inside-out process implies that internal knowledge becomes 
accessible for external actors by selling or licensing IP rights or investing in collaborations 
with external actors. The coupled process is a linkage between the outside-in and the inside-
out processes and implies that two (or more) parties merge for a project to take advantage of 
each party’s specific knowledge. The importance of both giving and receiving in the coupled 
process in order for the parties to benefit from the collaboration to a greater extent is also 
emphasized (Gassmann & Enkel, 2004).  
 
In order to utilize this model effectively, companies need to be able to capture all the benefits 
of their relationships with external technology providers (Fetterhoff & Voelkel, 2006). This 
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can create value and five key stages that generate value can be found. 1) Companies need to 
seek opportunities; the bigger the inflow of ideas the greater the chance to come up with 
successful innovations. 2) Companies have to rapidly evaluate their opportunities. One has to 
assume that competitors are searching for the same opportunities as well and that there will be 
pressure to quickly evaluate, sometimes even without complete data, in order to get a head 
start. 3) The recruitment process is taking place. Competitors are likely to opt for the same 
opportunity, thus to pursue the wanted partner of collaboration to enter a relationship is vital. 
This could be done through offering more money, by having a better reputation, the use of 
marketing strength, promotion of synergy etc. 4) Companies need to capture value. This is 
done through rapid commercialization where the uniqueness and utility of the innovation are 
shown. 5) The extension of the offer takes place by either finding new markets for the 
innovation or finding new additional features to it. This will nurture the relationship and open 
up for higher returns. 
3.5 Crowdsourcing 
Crowdsourcing means that many people outside the company (i.e. the crowd) are involved in 
the process of innovation. It could be customers, independent scientists or anyone who is 
interested in solving problems. The concept has become useful since companies have started 
to understand that there is wisdom to acknowledge outside company walls. Crowdsourcing is 
a type of Open Innovation as well as co-creation and user-creation, and a tool for companies 
to put outside ideas into their technologies and products, and moreover into processes too 
(Sloane, 2011). Pharmaceutical companies can use crowdsourcing to e.g. determine drug 
safety where patients’ opinions are valuable (Mintz, 2011). 
 
Crowdsourcing consists of four primary categories (Howe, 2008). 1) Collective intelligence 
(or crowd wisdom) which means that groups possess more wisdom than individuals. The 
crowd has talent and expertise that could earlier only be found within an academic 
environment, and these intellectual capital assets are now being tapped by progressive 
companies. 2) Crowd creation refers to the creativity among the crowd. The emergence of 
new technology in communication, first radios and later the Internet, created a platform for 
participation where committed and connected individuals were able to put up their ideas. A 
strive to exceed the existing standards or incentives such as enhanced status when solving a 
problem contribute to the creativity. 3) Crowd voting implies that crowds have the possibility 
to organize and handle enormous amount of information. Websites use systems that rank their 
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content after views, likes or downloads in order to make it easier for people to see what is 
most popular. 4) Crowdfunding makes it possible to fund projects or organizations without 
having to rely on banks or other traditional sources. An example is the emergence of micro-
lending, generally performed by philanthropists from the Western world who fund small 
businesses from the developing world. 
 
Thomke and von Hippel (2002) put forward a user-creation approach where customers should 
act as innovators. First, the company needs to develop a tool-kit for the users that enables 
them to innovate. These tool-kits have to provide four capabilities; 1) some kind of simulation 
technology where the users can complete series of design cycles. 2) They need to be user-
friendly and within the design language of the users. 3) A collection of earlier tested products 
so the users do not have to try something that has already been tried. 4) Information about the 
company’s processes in order to avoid products that cannot be produced. Thomke and von 
Hippel (2002) state that there is a win-win situation here where a company can benefit from 
getting help to solve a problem at the same time as the user gets the product he or she wants. 
3.6 Protection of Intellectual Property 
In this section the meaning, importance and usefulness of IP rights will be explained. 
Furthermore, this section brings up the complexity that arises when referring to the protection 
of ideas and innovation at the same time as this should be implemented into a more open 
environment. 
 
To mention IP and Open Innovation together might seem contradictory since IP normally is 
associated with Closed Innovation and exclusivity while Open Innovation, as the name 
suggests, aims towards opening up the innovation process and to making ideas accessible for 
other actors. There are many kinds of IP rights that are used throughout today’s business 
environment such as patents, trademarks, copyrights and trade secrets, which normally aim at 
excluding others from the access to a company’s ideas and investments in R&D. Therefore, it 
is likely to be a conflict when trying to combine the two since Open Innovation allows for 
inflow and outflow of ideas while IP rights is set up in order to protect and keep innovations 
internally (Hall, 2010). However, IP rights and Open Innovation do not have to exclude each 
other, as a matter of fact, a freer market for trade of IP rights is one of Chesbrough’s 
definitions of Open Innovation (Chesbrough et al. 2006). Therefore, in order to fully be able 
to buy and sell innovations it is important that ideas are well packaged (i.e. detailed, concrete 
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and clearly defined) and come with a protection right.  
 
IP rights are considered as motivators for innovation, since innovation itself is very costly, the 
innovator needs to make sure that his invention is protected from being imitated in order to be 
able to take advantage of the success. This discussion, from here on, is limited to focusing on 
patents as protection of IP, which, however, is a big device itself. 
3.6.1 Patents 
A patent is a private right for the owner of the patent to exploit an innovation, and no one else 
is permitted to take use of the innovation in any form without the owner’s permission. Patents 
are also essential tools of innovation output since the inventive performance of countries, 
regions, technologies and firms are reflected within a patent (OECD, 2004; Intellectual 
Property Office, 2012). 
 
A patent is an intangible asset that has a certain value for the owner. There is no single answer 
to what the value of a patent is; it depends on the appreciated present value of the future sales 
of the product being patented or the investments the patent will attract (Reitzig, 2003). The 
rights to a patent can be sold and traded freely, and the importance of intangible assets for 
companies today is growing and can even exceed the value of tangible assets. In the mid ‘70s, 
an average company portfolio was composed of 20 per cent intangible assets and 80 per cent 
tangible assets, and today these numbers are reversed giving intangible assets a portfolio 
importance of approximately 80 per cent for many companies (O’Connell, 2011). 
 
A patent makes it possible to package an innovation, as opposed to e.g. trade secrets, and 
therefore a patent is tradable between the innovator and society, which makes IP protection in 
the form of patents an important element. Patents have many qualities, O’Connell (2011) lists, 
among others, five aspects that come with patent rights. 1) The exclusive right granted to the 
inventor. 2) The right to stop others from copying an innovation. 3) The means to clarify 
ownership. 4) The buying, selling and licensing of patents. 5) The return on R&D investment. 
For high tech companies, and pharmaceutical companies, patents play an important role in the 
question of profitability since a company needs to make sure that its high cost investment will 
be exclusive on the market for long enough to cover the high R&D costs of an innovation. For 
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low tech industries patents are not what is most important in order to be profitable; in these 
industries, focus is instead put into markets, customer base etc. (Mazzoletti & Nelson, 1998). 
3.6.2 Complications of Intellectual Property rights 
Jurisprudence is an important and non-neglectable part of the innovation process and even 
more so when it comes to Open Innovation. Chesbrough et al. (2006) define Open Innovation 
such as the inflows and outflows of ideas and IP rights in a company. In order to be able to 
buy and sell IP rights, ideas must be well packaged which means that a well-defined and 
detailed patent should exist. This implies that the innovation is easily transferable and thus 
tradable. However, innovating together with competitors, academia etc. brings up the question 
of how IP rights should be handled. There is a risk that needs to be taken into consideration 
about which one of the parties involved in the process that should receive the ownership 
rights. The best solution to get around this sensitive but crucial issue is to be clear about how 
IP rights should be handled in the early phases of the project/collaboration, before any of the 
parties start investing time and efforts with a misconception about the situation. Some 
companies have very special rules considering IP, and it is thus necessary that all parties are 
clear about the conditions considering the new collaboration in order to avoid 
misunderstandings and unnecessary costs (O’Connell, 2011). 
 
Open Innovation has many advantages but there are also risks and disadvantages connected to 
a more open mindset about innovation and about taking on and sharing ideas with the external 
environment. First of all, if an innovation has been created in the open space, it might not be 
possible to call it a novelty and neither is it possible to apply for a patent for information that 
is public. Ownership is important, and it is crucial to decide which party that should receive 
the patent of a certain innovation (Hedner et al. 2011). When there are many stakeholders 
involved, contracts are usually set up before the collaboration begins in order to settle issues 
considering ownership rights, revenues from sales, access to the idea etc. 
When it comes to the question of treating IP rights as a part of Open Innovation and openness 
in the pharmaceutical industry, Kielstra (2011) states that this aspect of openness is the most 
complex and difficult of the two aspects of Open Innovation (the other one being to look 
outside company walls for external knowledge, ideas and skills). He also stresses the 
importance for pharmaceutical companies of allocating the IP from their own research 
effectively. The fact is that many companies develop ideas that are not directly useful or 
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connected to that company’s core business, and the innovation and idea might thus not be 
useful to the own organization at the end, even though it has been protected by e.g. a patent. If 
these innovations, in the form of IP rights, were to be easily tradable, companies would be 
able to make revenues on these investments, and thus increase cash flows and minimize their 
stock of unused IP rights. Only until recently, companies have been patenting as many ideas 
and innovations as possible, all according to the earlier mentioned closed innovation model, 
thus nothing was more important than a big IP rights-bank. Today, according to the Open 
Innovation paradigm, there is a slight shift of this attitude occurring.  Kielstra (2011) also 
concludes that today, an increasing number of companies have started to understand the 
difference between freedom to operate and of owning a certain patent.  
  
 
 
 
 20 
4. Empirical Study 
The fourth chapter begins with a description of the pharmaceutical industry and the process 
of drug development. The chapter continues with case studies of two pharmaceutical 
companies, AstraZeneca and Lilly, and their respective approaches to Open Innovation.  
4.1 Pharmaceutical industry 
Since the mid 20thcentury the pharmaceutical industry has delivered significant products and 
remedies to decrease human diseases and increase health worldwide (Munos, 2009). 
However, there is a decrease in productivity per dollar spent on R&D and innovations in the 
pharmaceutical industry today, and there are signs of stagnation (this issue will be further 
discussed below). Traditionally, drug development is characterized by close control of IP 
rights and of not allowing any transparency (Hedner, 2012). Due to the loss of productivity in 
the pharmaceutical industry as a consequence of increasing demands from costumers, the 
development of generic drugs and high failure rates, the traditional model of innovations has 
been increasingly questioned.  
When looking into the pharmaceutical industry, there are smaller and larger biotech and 
biopharmaceutical companies and there are the companies referred to as Big Pharma. As 
mentioned, these two groups can take advantageous use of each other. Biotech companies 
invest in particular R&D but lack of finances, knowledge of further development and of 
bringing an innovation from the laboratory to the market. Big pharmaceutical companies, in 
turn, are capital strong and established companies that have the capabilities to develop 
innovations and can thus provide smaller biotech companies with these capabilities. In 
sciences such as biotechnology, pharmaceutical companies cannot fall back on any 
incorporated knowledge and are thus dependent on collaborations with biotech companies. As 
an example, most advances in molecular biology and genetic engineering have been made not 
by pharmaceutical companies in-house but by specialized biotechnology firms and scientists 
(Senker, 1996). Big pharmaceutical companies have not succeeded fully in building up their 
own competencies when it comes to biotech, and thus make more efficient use of both their 
own resources and of those of biotech companies when exploiting the knowledge of the latter.  
The pharmaceutical industry is knowledge intense, and it takes a long time to develop and 
introduce a new drug to the market as a result of long and expensive R&D. This is given 
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considering the nature of this industry, which has its roots in herbal medicines and natural 
remedies. Pharmaceuticals once emerged only in order to cure diseases but have, as time has 
proceeded, become more and more an issue of business and a product of the investment 
policy of any given pharmaceutical company. Today, there is no industry as complex as the 
pharmaceutical industry when it comes to doing business and making money. This has a lot to 
do with, as mentioned, the origin of pharmaceuticals. The reason for the complexity of the 
pharmaceutical industry thus emerges from the moral dilemma created by the requirement of 
profit maximization from a product that in its nature is purely philanthropic. However, profits 
and revenues are crucial for any company that wants to stay in business and develop its 
strategy, and the reason why return on investment is so important for a company in the 
pharmaceutical industry will here be further discussed. 
It is easily understood that in order to survive as a business, costs and revenues need to be at 
least on a break-even basis (it is of course preferable to have revenues exceeding costs in 
order to make profit and thus be able to invest in future projects, product development, 
innovations and other ventures). As a fact, a new molecular entity takes on average, from idea 
to market launch, about 12 years and require investments from $ 800 million up to $ 4 billion 
(Hedner, 2012). A patent normally lasts 17-20 years from the registration date (which 
normally is when the idea of the new combination of molecules is dated), which means that 
the investment costs need to be covered during the 5-8 years that are left of the patent when 
the new pharmaceutical is launched (Swedish Patent and Registrations office, 2012). It is 
simple to understand that all costs need to be covered during the lifetime of the patent; 
however, the complexity lies within the difficulty of covering these high costs in such little 
time. These numbers clearly indicate that the drugs beneficial enough to develop are those 
that cure relatively common diseases that are high in demand of a clientele with strong 
purchasing power. The questions are consequently; 1) What about diseases that are rare? 2) 
What about diseases that strike those with less or no purchasing power? The fact is that the 
minor incomes these medicines would generate are much too small in order to cover R&D 
costs, nonetheless to provide a pharmaceutical company with profit margins. Therefore so 
called blockbuster pharmaceuticals (e.g. Viagra and Prozac) are drugs that pharmaceutical 
companies are most willing to invest in since these are high in demand of a rich segment of 
the world’s population who will be able to pay enough in order to cover the high costs of 
R&D (Kielstra, 2011). (Naturally, more narrow and specific diseases are weaker in demand 
and thus less likely to be able to cover costs of investment, and the same goes for common 
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diseases, such as malaria, that strike people with low purchasing power.) To summon this up 
it can be said that there is a decline in the development of pharmaceuticals today at the same 
time as larger and larger investments are observed, thus the need for new innovations is ever 
so strong but the power of capital and blockbuster medicines thwarts further innovations as 
the situation is today. Chesbrough (2011) concluded this dilemma in a suitable way by saying 
that the perceived need for blockbusters has shattered many promising compounds that could 
have been profitable products. According to Chesbrough (2011), it is true that only so called 
blockbuster drugs can raise the kind of money needed to generate profit as return on 
investment for pharmaceutical companies. What Open Innovation can do for a company in 
this situation is that it allows for companies to learn from each other about what could go 
wrong in a certain research process and thus it does not have to invest time and money in 
executing the same experiments. Open Innovation can be a tool for developing new 
innovations and decreasing investment costs. This leaves more room for researching other 
profitable ideas that are of non-blockbuster characteristics (Chesbrough, 2011). 
4.1.1 Drug discovery and development process 
In order to understand the empirical results of this thesis, a thorough review of the drug 
discovery and development process will be outlined below. The chapter explains the process 
in USA, but should serve as an overview of the process in general. 
 
According to the Pharmaceutical Research and Manufacturers of America (Phrma) (2007), the 
first part of drug discovery and development process is called discovery and starts by gaining 
an understanding about the disease that is going to be treated. When scientists have enough 
information about the disease it is time to select a target, which generally is a single molecule 
that is going to be targeted with the potential drug. The target is then tested and validated to 
make sure it is promising as well as to prevent companies from proceeding with targets that 
will lead to dead ends. Next step is to develop a molecule, which is called lead compound, 
which will interact with the target. The compounds will go through a number of tests to make 
sure that they are safe and that the finished drug can be absorbed into the bloodstream, 
metabolized effectively and shown not to be toxic. Scientists also have the possibility to alter 
the structure of compounds in order to improve them. 
 
After these steps, it is time to start testing the compounds more intensively. There are two 
types of tests within this stage: in vitro and in vivo. In vitro means that a compound is being 
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tested in a test tube and in vivo refers to tests on living cell cultures and animal models. It is 
extremely important to find out that the drug is safe enough to later be tested on humans. In 
this step the process of large quantity production will be figured out as well. In the end, the 
initial 5,000 to 10,000 compounds will be scaled down to between one and five potential 
candidate drugs. 
 
The pharmaceutical company then proceeds to development, which consists of clinical trials. 
First, the company must file an Investigational New Drug (IND) application with the U.S. 
Food and Drug Administration (FDA) where the results from its pre-clinical testing are 
included, chemical structure, how it will work, side effects, a detailed trial plan and 
manufacturing information. The company also needs an approval from the Institutional 
Review Board (IRB) who will ensure that all the people in the trial consent to the tests and 
know what they sign up for. FDA has the power to stop the trial if problems occur and reports 
how the trial proceeds need to be sent to them. 
 
The clinical trials consist of three phases. In the first phase a small number of healthy persons 
take part in it and the main goal is to find out whether the drug is safe for humans or not. 
Scientists also make an effort to determine if the drug can be absorbed by the bloodstream and 
other features as those mentioned above. In the second phase, the researchers evaluate the 
drug’s effectiveness by testing it on patients with the disease it is suppose to treat. Further, 
scientists look at the risks and side effects to decide if they will continue to the third phase. In 
the third phase the researchers test the drug on a larger number of people with the disease 
where they, to a greater extent, can confirm that the drug is safe for humans and that it is 
efficient for the intended disease. This is the phase that takes the longest time and carries the 
highest costs. 
 
After the third phase is completed, the company sends a request to FDA to get the drug 
approved. The FDA addresses three major concerns: if the benefits outweigh the risks, what 
information the package should contain and if the manufacturing process is good enough to 
ensure the quality of the product. After an approval, the company can start manufacturing the 
drug, which could be complicated due to the large scale. The company will subsequently 
monitor the drug after it is produced and report periodically to the FDA. There could also be a 
fourth phase where the company conducts additional studies to investigate, for instance, long-
term safety (Phrma, 2007). The whole process is summarized in figure 4.1. 
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Figure 4.1 Drug Discovery and Development Process (Phrma, 2007) elaborated by the 
authors 
4.2 AstraZeneca 
Astra AB was founded in 1913 with the headquarters in Södertälje, Sweden (AstraZeneca, 
2012b). It started as a simple manufacturing pharmaceutical company but turned its focus 
towards being a more research oriented firm in the 1930s. This led to the invention of 
Xylocaine, a local anaesthetic, which in 1948 became the company’s breakthrough on the 
market of pharmaceuticals (Schön, 2009). Another pharmaceutical that Astra is known for is 
Losec, an ulcer drug that was the world’s top selling pharmaceutical in the early 2000’s 
(Macalister, 2001). 
 
Zeneca Group PLC was spun out as an independent company from chemical giant Imperial 
Chemical Industries (ICI) in 1993 to focus on pharmaceuticals, agrochemicals and specialties 
(AstraZeneca, 2012b). Zeneca had a wide-ranging international development and key 
products within oncology and the cardiovascular medicine (AstraZeneca, 2012b). 
 
In 1999, the two companies merged to form AstraZeneca. The merger was due to the fact that 
the two companies were both involved in the same fields of research such as cardiovascular 
and respiratory pharmaceuticals, as well as to enhance long-term growth and sustain 
shareholder value (AstraZeneca, 2012c). The company set out three main focuses where these 
objectives would be met; combining global power in sales and marketing in key areas such as 
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cardiovascular, oncology, anaesthesia and respiratory medicine, focus on improving and 
enhancing R&D, and use increased financial strength to improve strategic flexibility.  
 
In 2011 AstraZeneca had revenues of $33.6 billion and was ranked as the 8th largest 
pharmaceutical company in the world according to Forbes (2012). The company spent $5.5 
billion on R&D in 2011 and it involved 11,300 people in 14 research centres in eight 
countries (AstraZeneca, 2012d). AstraZeneca’s mission statement is: “to make the most 
meaningful difference to health through great medicines that bring benefit for patients and add 
value for our stakeholders and society” (AstraZeneca, 2012e). 
 
Lately, AstraZeneca has been restructuring its business and the restructuring has involved 
many layoffs in Sweden (Kollewe & Neate, 2012). The reason why the company is 
undertaking these actions will be further explained in interviews with company 
representatives and is mainly due to the need of being flexible in order to be able to adapt to 
changes in the industry globally. 
4.2.1 Innovations at AstraZeneca 
In order to reach its over-all goal, to improve health worldwide by creating medicines that 
aids the world’s growing and aging population, AstraZeneca looks outside company walls and 
commits to partnerships (AstraZeneca, 2012f). To AstraZeneca, as to any company in the 
same industry, innovation is one of the most important aspects of the company’s business and 
future profitability. AstraZeneca has, according to the company’s CEO of Sweden, Anders 
Ekblom (also Executive Vice-president for Global Medicines Development), always been 
engaging in collaborations and partnerships with different institutions and companies. To Dr. 
Ekblom, the definition of Open Innovation; “to acknowledge and look for external 
knowledge, skills, innovations and talents” is thus nothing new for AstraZeneca. Dr. Ekblom 
also adds that today AstraZeneca has more than 1000 different collaboration/partnership 
agreements globally, where about 200 of these have been set up in Sweden (see table 4.1). 
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5 Key late-stage deals 2009-2011 
60 Significant deals completed 2008-2011 
67 % Of potential near term launches through collaborations 
50 % Of projects in phase II are sourced from alliances 
40 % Of our pipeline is sourced from outside our laboratories 
 
Table 4.1 Numbers of AstraZeneca’s Collaborations and Partnerships (AstraZeneca, 
2012f) elaborated by the authors 
 
AstraZeneca is a company that invests a lot in partnerships and collaborations. Shaun Grady, 
AstraZeneca’s vice president of Strategic Partnering and Business Development, states that 
the company has engaged in collaborations for over 30 years, both with other companies, 
investors, non-profit organizations, institutions and authorities and with patient groups 
(AstraZeneca, 2012g). 
4.2.2 External knowledge 
Collaborations are essential for companies like AstraZeneca that aims to work with the 
world’s best scientists and researchers. In order to always stay updated about new innovations 
and possibilities to invest, AstraZeneca has developed the so-called iMed-group that 
continuously searches externally produced/invented medical preparations that can contribute 
to the internal development of AstraZeneca’s own innovations, either as a complement to the 
companies existing products or as something to develop in-house. AstraZeneca states that the 
company possesses the knowledge and the resources required in order to enable strategic 
partnerships with other actors irrespective of their size. These partnerships serve as 
complement to AstraZeneca’s own business activities, and the company claims that these 
collaborations contribute as a step towards becoming the leader of R&D when referring to 
human diseases (AstraZeneca 2012h).  
 
There are two aspects of the process when AstraZeneca is looking for external knowledge and 
partners to collaborate with. First of all it is necessary to realize that in an organization with 
many researchers, such as AstraZeneca, a big part of the company consists of researchers 
coming directly from universities. These researchers come from an academic environment 
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and have disputed and worked at the university before coming out to the company. They are 
thus already used to collaborating, have their own network of skilled peers and know how to 
socialize and collaborate in both virtual contexts and conferences. Dr. Ekblom explains that 
this fact implies that the researchers, on their own, look for external knowledge and that the 
active search for external knowledge, ideas and talents is something that AstraZeneca’s 
employees conduct on a daily basis. However, this is not the only way AstraZeneca is looking 
for the best research on the market. The company has also developed groups called Business 
Development Groups for five different medical units that focus on different disease areas 
where scientists and strategists scout the world for the best ideas, the newest research, the 
most profitable companies and analyze current situations on the market of pharmaceuticals. 
There are also certain researchers that focus not on specific diseases but on specific 
companies in order to map out what these certain companies currently have in their pipeline. 
In addition to these two processes of looking for external ideas, researchers continuously read 
articles and new reports in order to detect new ideas and thus create an internal eco system.   
 
How external knowledge and sources are evaluated can be explained by two factors according 
to Mats Sundgren, Principal Scientist within Global Clinical Development at AstraZeneca 
R&D: 1) a safety perspective is considered when evaluating whether an external 
innovation/project/drug should be acquired. This means that AstraZeneca values 
innovations/projects/drugs higher if the information given about these can assure that there 
will be no side effects, i.e. the rate of development of the drug affects the value of it since a 
drug with high rate of development implies less costs and risks than a drug in the early 
development phase. 2) AstraZeneca also evaluates different innovations/projects/drugs from 
what existing competition this product in particular faces. Also, patents are an important part 
of the evaluation process and AstraZeneca always wishes to be able to acquire the ownership 
rights. 
4.2.3 AstraZeneca and Open Innovation 
AstraZeneca is strategically located in two places in Sweden; Södertälje outside Stockholm 
and Mölndal outside Gothenburg (AstraZeneca 2012i). These locations are geographically 
close to prosperous universities, university hospitals and research units. Dr. Ekblom explains 
that in environments where academia is accessible, Open Innovation processes and 
collaborations in general are more easily enabled. He adds that AstraZeneca originally 
collaborated with universities in order to develop new drugs and lately the company’s 
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collaboration portfolio has become more diversified and now includes many bigger 
companies too, so-called peer-to-peer collaborations. In the pharmaceutical industry today, 
and especially for Big Pharma, there is a need for external research and innovations from both 
other companies in biotech and from academia in order to decrease lead times and implement 
more efficient research strategies to escape the trap of low productivity. Academics and their 
knowledge are very important and open source plays a big and significant role in new 
innovations. (Kielstra, 2011) 
 
According to Dr. Sundgren, Open Innovation has three imperative parts; 1) Self direction; 
those working with a project can do so in an independent way which leads to engagement and 
collaboration. 2) Mastery; those working with a project get the chance to improve what they 
are doing. 3) Purpose; a higher utility than the project itself needs to exist in order to 
participate. If the three parts exist, a collaboration has every opportunity to become 
successful. Dr. Sundgren explains that this openness interrupts the classic model where a 
company considers itself to possess most knowledge and talents in-house. There are several 
levels where openness can occur such as in the earlier phases of R&D and in other stages later 
in the development phase. However, he adds that the definition of “openness” is vague and 
must be seen as the opposition of “closed” in order to make any sense. Examples that 
illustrate openness and Open Innovation at AstraZeneca are alliances and partnerships that the 
company conducts to a greater magnitude than earlier. One example in particular is the 
development of a drug created in order to treat type II diabetes, where AstraZeneca 
collaborates with the pharmaceutical company Bristol Myers Squibb. The two companies 
share the work in the clinical process and they both benefit from reduced risks and costs. All 
AstraZeneca’s collaboration projects are deeply depending on well-detailed and worked-out 
contracts, states Dr. Sundgren.  
 
In a press release published in January 2012, AstraZeneca presented a new R&D function that 
focuses on access to new technology and innovations in the industry and on Open Innovation. 
This new initiative is called the Science and Technology Integration Office and Dr. Ekblom is 
announced the head of the new R&D function. One of the focus areas of the Science and 
Technology Integration Office is to identify and develop future trends within science and 
technology, Open Innovation and on strengthening AstraZeneca’s inputs around 
collaborations before market launch (AstraZeneca, 2012j).  
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AstraZeneca needs to focus on coordinating its inputs more efficiently and focus on a smaller 
number of research projects in order to reach faster, better and cheaper results. Dr. Ekblom 
states that it will be important for AstraZeneca to break new grounds, to be where cutting 
edge innovations emerge and to get there with an opened mindset and the acknowledgement 
of the phenomenon Open Innovation (Kielstra, 2011). 
 
As other sources confirm, both Dr. Ekblom and Dr. Sundgren explains that as a consequence 
of globalization, the fierce competition in the pharmaceutical industry becomes murderous. 
The competition is a consequence of increased living standards which lead to more developed 
education systems in emerging countries which in turn means that there will be more 
competent people around to develop new molecular units. Dr. Sundgren adds that it is of great 
importance to prolong the product lifecycle of the company’s products in order to extend the 
time any given product generates incomes. Furthermore, he adds that he believes AstraZeneca 
to have succeeded in doing this when it comes to certain products by successful positioning 
providing customers/patients an advantage in using the particular drug.  
4.2.4 Pre-competitive collaborations 
As previously mentioned, the conception of how Open Innovation is defined is an important 
element of this thesis. AstraZeneca’s conception of Open Innovation leans towards a 
combination of Open Innovation and so-called “pre-competitive collaboration”. Pre-
competitive collaboration refers to the situation where companies collaborate in order to 
develop methods and techniques that are needed in the industry without competing (Weigelt, 
2009). Furthermore, Dr. Ekblom states that AstraZeneca’s goal is to achieve faster results and 
initiate new collaborations with other companies, academia, non-profit organizations, 
authorities and investors. 
 
Dr. Ekblom explains that what will be new in this R&D function will not be the collaborations 
but rather something called pre-competitive collaboration projects. The idea is that standards 
and instruments for measurements, such as biomarkers, should be developed to a lower cost 
when many companies invest in the development instead of just one. One example is the 
development of a drug to treat Alzheimer’s disease. Today there are no biomarkers to measure 
certain reactions in the brain or in the blood of patients with Alzheimer’s disease and 
therefore companies collaborate to develop a standardized measurement system of biomarkers 
that allows for all pharmaceutical companies that do research within the field of Alzheimer’s 
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disease to use these biomarkers. Later on, when a company like AstraZeneca performs clinical 
test studies, which it conducts in over 50 countries and with over 1000 hospitals, it is 
beneficial to have a standardized and accepted way of measuring these biological reactions. 
Dr. Ekblom explains that for AstraZeneca, the development of biomarkers like this is nothing 
the company wants to engage in solely; on the contrary he explains that AstraZeneca 
competes with the development of the best drug, not the best biomarker. However, Dr. 
Ekblom states that AstraZeneca also invests in so-called pre-competitive/competitive 
collaborations where a number of companies collaborate to develop new biomarkers for tests 
made when developing drugs. The difference between pre-competitive collaborations and pre-
competitive/competitive collaborations is that in the former it is normative that all data is 
published when the latter allows for the involved companies to exclusively exploit the new 
innovation. The benefits of collaborating to develop measurement instruments, such as 
biomarkers, are decreased time and costs of development. After the development of these 
instruments the data will normally be published and opened for any hospital or 
pharmaceutical company to apply. This is thus what is called pre-competitive collaboration 
and is, according to AstraZeneca, Open Innovation. 
4.2.5 Private-Public Partnerships 
Something else that is new to AstraZeneca and to the pharmaceutical industry in general is so-
called Private-Public Partnerships (PPPs). These are projects conducted between a few 
companies together with governments, non-governmental organizations (NGOs) or other 
public instances. The difference between a PPP collaboration and a pre-competitive 
collaboration is that something developed in a PPP agreement will almost exclusively be truly 
open since tax money cannot finance competitive projects. This implies that data developed in 
a PPP agreement will be available for anyone, and within a pre-competitive collaboration 
exclusivity can be created and data can be available only for those who invested in the project. 
Dr. Sundgren comments that due to the nature of most PPP collaborations, i.e. that they are 
fully transparent, pharmaceutical companies could take use of PPPs in order to improve their 
reputation. One example of a PPP collaboration is Innovative Medicines Initiative (IMI) that 
is a European collaboration project where big pharmaceutical companies collaborate with 
smaller biotech companies, academia and institutions to develop new drugs. Dr. Ekblom and 
Dr. Sundgren agree that these kinds of collaborations are important to AstraZeneca since the 
company gains much knowledge by participating. IMI is also significant since it contains 
immense finances and it is of interest for AstraZeneca (and other companies) to get access to 
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expensive research that is not possible for the company to achieve otherwise since essential 
information is shared within an IMI-project by prominent companies in the industry as well as 
by qualified academia. Dr. Sundgren states that the usage of PPP collaborations such as IMI is 
a new way for the industry to work and differs to great extent from traditional, in-house R&D. 
Furthermore he denotes that the IMI projects apply three aspects: 1) Background, which 
determines what knowledge the company is entering a certain collaboration with. 2) 
Foreground, which explains what is generated from this particular collaboration. And 3) 
Sideground, which is the additional factors needed to be considered, such as IP rights. These 
three bullet points of IMI collaborations are needed in order to clearly demonstrate the 
benefits and/or uncertainties of a particular collaboration. The lower costs and the spreading 
of risks are essential factors. There are, despite the advantages of PPP, certain disadvantages 
that cannot be ignored. Dr. Ekblom explains that critique directed towards IMI and other PPP 
projects is that much bureaucracy is involved which leads to long lead times and makes the 
process complicated. 
4.2.6 Crowdsourcing 
When it comes to the subject of crowdsourcing in the pharmaceutical industry, open platforms 
such as Patientslikeme.com (a digital platform where patients share experiences concerning 
their diseases) are often discussed. Dr. Ekblom and Dr. Sundgren both agree that the industry, 
and AstraZeneca in particular, needs to begin to connect to patients in a new way in order to 
attain the existing information they possess. Dr. Sundgren explains that patient information in 
general, e.g. re-use of patient data, could aid AstraZeneca in the R&D process. In order for 
such a function to be beneficial for the company the re-use of patient data would have to be 
executed with great transparency.  
Dr. Sundgren adds that he believes such user platforms to have gotten much attention due to 
the fact that the users see a personal benefit in using the platform. He adds that if AstraZeneca 
could learn how to further engage patients in an ethical and legal way many costs could be 
reduced and make big difference for the company in the innovation R&D process. Dr. 
Ekblom considers platforms such as Patientslikeme.com something that AstraZeneca could 
take use of when it comes to developing remedies for so called orphan diseases. The World 
Health Organization defines orphan diseases as rare diseases that trouble 0.65-1 in 10,000 
people (Lavandeira, 2002). If a drug to cure an orphan disease is developed, the legal aspects 
of this drug look a little different than those of drugs to cure normal diseases. There are fewer 
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requirements for orphan drugs, and the period for exclusivity is prolonged in order to allow 
for the company to have a better chance at covering high R&D costs. However, Dr. Ekblom 
comments, the problem in cases like this is that in the end the R&D costs for orphan drugs are 
still very high and create problems. Dr. Ekblom further states that AstraZeneca is sure to use 
crowdsourcing to a higher extent in the form of open platforms in the future, however, he 
admits that the company does not have the knowledge of how to take advantage of open 
source information as it is today. Today, AstraZeneca uses platforms and crowdsourcing 
when evaluating already existing drugs; one example of this is the Internet site astma.com. Dr. 
Ekblom says that he sees a future for crowdsourcing at AstraZeneca and in the pharmaceutical 
industry in general when it comes to developing orphan drugs and in monitoring diseases over 
time.  
 
When talking about AstraZeneca and Open Innovation it can be said that it is important for a 
company to innovate but also to learn how to innovate and look for new ideas. Dr. Ekblom 
explains that AstraZeneca continuously works with examinations of other companies’ 
strategies and ways to innovations and success, not only in the pharmaceutical industry. 
AstraZeneca’s leadership teams have a lot of out-visits and in particular to companies outside 
the pharmaceutical industry in order to understand what other people are doing and what there 
is to learn. Dr. Ekblom also states that it is important to ask questions like “Why can Google 
be successful?” And “What would that mean for us?” (Kielstra, 2011). Thus Open Innovation 
is a phenomenon that is not exclusively adoptable for one industry, but a strategic tool that 
companies from different industries can benefit from and also learn from each other’s 
adaptations of this strategy. 
 
The pharmaceutical industry is slow to adapt to the Open source and the crowdsourcing 
models, and Dr. Sundgren states that there are several examples of crowdsourcing where 
companies do not take any risks at all and in return achieve less complicated knowledge 
provided from “the crowd”. Therefore, he suggests, a more sustainable approach that focuses 
on continued collaborations that provide value for all parties involved would increase the 
results of the usage of crowdsourcing. The value chain between producer and consumer has 
changed lately, denotes Dr. Sundgren. Earlier the communication between the pharmaceutical 
company and the patient has been more or less a one way such. However, today it is of great 
importance that the consumer, i.e. the patient, receives more attention. The development of 
Information and Communication Technology (ICT) has empowered the role of the individual 
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and Dr. Sundgren states that he believes it to be necessary for the whole industry to realize 
this and go towards a more patient centered and market driven business model.  
4.2.7 Future challenges 
In the pharmaceutical industry, the market launches of new drugs per dollar invested have 
decreased lately and it is clear that managerial and strategic actions need to be undertaken in 
order to cover R&D costs (Hedner, 2012). Open Innovation has been discussed as a solution 
to this kind of complexity that could help both smaller biotech companies and Big Pharma to 
remain profitable and innovation strong. AstraZeneca, too, acknowledges this by admitting 
that increased R&D costs and decreased revenues are problems both for AstraZeneca but also 
for the entire industry. Every year the company invests billions of dollars in R&D that needs 
to be covered by drug sales (AstraZeneca, 2012h). Therefore AstraZeneca is firmly 
determined to focus on the core areas of its business, i.e. cancer, infections, heart/blood-
vessels, stomach/colon, neuroscience and respiratory ways and inflammations in order to 
better assure that R&D costs will be covered.  
 
When it comes to the future of Open Innovation in the pharmaceutical industry, the question 
can be posed such as “will companies collaborate further in the future?”. The answer to this 
question is, according to researchers and strategists in the pharmaceutical industry, 
doubtlessly yes. The question then is why? There are a few explanations that all play 
important roles. Firstly, people realize that knowledge is wide spread today due to emerging 
markets such as the BRIC- countries (Brazil, Russia, India and China) and the number of 
intelligent people who have something to contribute with is continuously growing. 
Pharmaceutical companies then want to be where break trough science arises, and Dr. Ekblom 
means that this fact will be a driving factor of future development of Open Innovation. In 
addition, Dr. Sundgren states that Open Innovation is believed to become a natural part of the 
pharmaceutical industry and will, to great extent, affect how companies engage in 
collaborations. He adds that the industry is going through certain changes, and that 
collaborations, partnerships and alliances will become a given factor in the product innovation 
process. The second aspect of further collaborations is that the costs of driving innovations is 
constantly increasing, and it is thus crucial for the business and for the industry to become 
better at finding more cost efficient solutions. Dr. Ekblom illustrates the problematic by 
saying that output from the industry has been constant for the last 20-30 years with about 25 
new drugs launched on the market every year globally, and when looking at the research 
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budget for each year it has increased dramatically. There is hence no increase in product 
development even though there is an increase in costs, which implies a decreasing 
productivity. In addition to this, incomes from sales have also decreased due to the fact that 
consumers of drugs demand more per dollar spent and also the competition of generic drugs 
has become more and more efficient. This means that when the lifetime of a patent comes to 
an end, the producers of generic drugs quickly launches their version of a drug to the market 
but to a much lower price. Dr. Ekblom states the example of an American actor in the 
pharmaceutical industry that was getting incomes from sales of $1 billion one day, 14 days 
after the company’s patent became too old sales would drop to $100 million and in another 14 
days sales would be no more than $60 million. This is a serious change in income today that 
used to take a couple of years. Today, healthcare and hospitals are aware of the expiration of 
patents and make sure to shift their consumption from the original brand to a generic brand 
the day of expiration of a patent.  
 
Gazing to the future, AstraZeneca is open to engage in more projects such as IMI and Dr. 
Ekblom and Dr. Sundgren state that it is imperative to join the trend of increased 
collaborations in order for the company to be considered an attractive partner. However, Dr. 
Sundgren adds that it is still important for AstraZeneca to find a portfolio balance between in-
licensed, external innovations and innovations developed in-house, i.e. closed innovation. He 
suggests a balance of 30 per cent of the portfolio to consist of products developed in-house in 
order to maintain the control of the vision of what direction the company wants to drive its 
innovations. 
The industry as a whole is going through changes; however it is hard to determine what is the 
root and what is the reaction when it comes to the case of AstraZeneca. What is clear is 
though to have an organizational structure that is adaptable to these changes, and thus to 
different kinds of collaborations and partnerships and Dr. Sundgren is convinced that this is a 
central factor for the future of AstraZeneca. He denotes that the organizational structure thus 
should be self-directed and have smaller, faster units that are more easily connectable. 
Organization wise it is also important to change and if smaller companies are acquired these 
companies still need to work as independent and efficient units. Thus, an organizational 
structure that meets these requirements of Open Innovation needs to be implemented. It is a 
big challenge to adapt such a business structure, however, AstraZeneca has realized the 
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importance of smaller, independent units of the company, such as the Business Development 
groups, in order to be a more flexible and adaptable organization rather than one big entity. 
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4.3 Eli Lilly and Company 
Eli Lilly and Company (referred to as Lilly) was founded in 1876 in Indianapolis, USA (Lilly, 
2012a). Throughout the years, Lilly has come up with a number of well-known products 
where Prozac is the most prominent and the company was also the first company to mass-
produce penicillin (Schwartz & Huff, 2010). 
 
Today the company has more than 7,400 employees working with R&D and its products are 
marketed in 125 countries. In 2011, Lily spent more than $5 billion on R&D in its facilities in 
eight countries around the world and R&D costs represented as much as 21 per cent of the 
company’s sales that year. Lilly is the world’s 9th biggest pharmaceutical company and thus 
one of the Big Pharmas (Forbes, 2012).  
 
In the late ‘90s Lilly initiated a more open approach in its R&D. It had already conducted 
successful collaborations, as in the case of the mass-production of penicillin together with the 
University of Toronto, and now it wanted external ideas into its development of new products. 
An Office of Alliance Management was created to imply this strategy and Lilly was the first 
company in the pharmaceutical industry to establish this and to use Alliance Managers to 
supervise partnerships (Schwartz & Huff, 2010). Lilly chose to be very open in its approach 
and the company hoped that this would lead to a reputation of Lilly being among the best in 
the industry as well as a company that wanted to collaborate with other companies. The 
strategy turned out to be successful and led to the production of pharmaceuticals such as 
Cialis (with ICOS) and Byetta (with Amylin), and these drugs were developed because the 
companies were able to align their strengths (Schwartz & Huff, 2010). In addition, 
partnerships that led to in- and out-licensing of technology rather than drug development were 
also formed.  
 
Schwartz and Huff (2010) point out that one of the key factors of these partnerships was that 
Lilly consistently used “alliance health scorecards” (see figure 4.2), which made it possible to 
see the performances of different dimensions over time within the partnerships. The levels to 
which the lines in the figure are drawn show to what extent different aspects are achieved 
within a partnership. The data was compiled through surveys among those related to the 
partnership. These scorecards have helped Lilly to minimize risk and to establish itself as a 
company that is willing to collaborate with others.  
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Figure 4.2 Lilly’s Balance Scorecard (Schwartz & Huff, 2010) elaborated by the authors 
4.3.1 InnoCentive 
Lilly was facing the same issues as other pharmaceutical companies when trying to develop 
new products, and in 2001 Lilly’s patent for Prozac expired. Prozac made up for 34 per cent 
of the company’s revenue, thus it had to come up with a new market-leading product to 
remain competitive in the industry (Breen, 2002). Besides trying to invent a new blockbuster 
drug the usual way with internal R&D, Lilly also tried a different approach. In 2001, Lilly 
created InnoCentive, a problem-solving platform, which would increase its access to far more 
scientists and ideas.  
 
In the beginning InnoCentive was a web site where scientists from Lilly could post their ideas 
and other scientists all over the world would have the possibility the view the problems and 
try to solve them (Schwartz & Huff, 2010). InnoCentive grew fast and other pharmaceutical 
companies as well as companies from other industries began to post their problems on the 
site, and today InnoCentive works as an independent company (Wessel, 2007). By letting 
other companies use the problem-solving platform, Lilly was able to share the risks and costs 
of the project with them (Chesbrough & Garman, 2009). Companies that post their problems 
are called “seekers” and the scientists who try to solve them are called “solvers” (Allio, 2004). 
The solver needs to sign an agreement before he or she is able to see problems (which are 
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posted anonymously) (Breen, 2002). The solver with the best solution is then given a reward. 
The reward is usually between $10,000 and $20,000 if the problem is solved without the need 
of a laboratory, and from $35,000 to $100,000 if the problem is more complicated and 
requires a laboratory to be solved (Allio, 2004). In the end, it is up to the seeker to determine 
the amount. 
 
The CEO of InnoCentive, Darren J. Carroll, explains it is an innovative approach because it 
asks research questions that earlier was handled secretly within the company (Allio, 2004). 
InnoCentive has also found a way to make the research problems available to external 
scientists all over the world and convinced them that this marketplace could give them 
something in return if they contribute. He further describes how InnoCentive has qualified 
scientists with skills in different areas that help to attract seekers by making posted problems 
easier to understand and to screen out the solutions that do not meet the criteria (Allio, 2004). 
The seeker scientists have the final say and write a report to InnoCentive who gives feedback 
to solvers on their solutions.  
 
Carroll also explains how solvers are protected (Allio, 2004). Solutions that are sent in will 
remain confidential as well as the solvers communication with InnoCentive. Seekers have 90 
days to use a solution that is submitted by a solver. If the seeker chooses to use it; the seeker 
receives the patent if the solver accepts the reward. If the seeker does not choose to use it, the 
scientific staff makes sure that the seeker does not use the solver’s patent. InnoCentive also 
has an audit provision that ensures that solvers are not being mistreated.  
 
Even though InnoCentive is an independent company today, Lilly has been able to use the 
platform in its Open Innovation process differently than it first did. Lilly collaborated with 
InnoCentive to create a tool to get hold of ideas within the company (Schwartz & Huff, 2010). 
It is called InnoCentive@Lilly and is a platform where inside seekers are being matched with 
inside solvers - an Open Innovation approach of reaching its internal employees. The 
problem-solving rate was 80 per cent in 2009, which was the same as Lilly’s problem solving 
rate in the external InnoCentive network. 
 
InnoCentive has been criticized for its model. A chemist who has been awarded for a solution 
believes that the solver is taking too much of a risk because he or she could be working for 
months without getting anything in return, while the seeker takes on no risk at all (Breen, 
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2002). Carroll responds that this is the idea and that it is up to the solver to determine whether 
the risk is worth taking. 
 
InnoCentive can also be seen as a way of crowdsourcing. Howe (2008) points out that there 
are 140,000 scientists from more than 170 countries that log on to the website to find 
problems they are eager to solve. Companies reach out to anonymous people instead of 
looking for potential collaborations with smaller enterprises (or universities as in the case of 
the “Open Innovation drug discovery” below). Howe (2008) further mentions two aspects that 
make InnoCentive work and how it operates: 1) It takes down barriers to participation which 
leads to access to intellectual capital all over the world that otherwise would be hard to reach. 
2) It does not matter if you are a professional or an amateur. Since actors in the network come 
from all corners of the world they all have different experiences and can see things in other 
ways than the scientists in a company. Today giant companies such as P&G, DuPont, NASA, 
Roche and BASF are posting their problems on the web site, which show how successful it 
has become (Busarovs, 2011; Howe, 2008). 
4.3.2 Chorus 
Chorus was created as an autonomous experiment division in 2001 with the aim to improve 
the early-stage drug development within Lilly (Bonabeau, Bodick & Armstrong, 2008). The 
team consists of industry professionals with many years of experience in areas such as 
toxicology, clinical operations and quantitative pharmacology (Chorus, 2009). The model 
evaluates a portfolio of molecules and only sends the most promising through to late-stage 
development where failures are extremely costly and hard to recover from. Chorus supports 
Lilly by generating proof-of-concept data quickly and cheaply, so that it is able to choose 
molecules more effectively and reduce uncertainty, and hence reduce the risk (Longman, 
2007). The term “proof-of-concept” means that a drug must be effective and show no signs of 
serious side effects (Bonabeau et al. 2008). Chorus plans for failure, i.e. it expects that most of 
the molecule compounds will fail (Longman, 2007). As a consequence, it will only make a 
minimum effort to figure out if a compound is going to succeed. It is expensive and 
unnecessary to figure out the manufacturing process and other related steps, when the chance 
of failure is high. These steps can be solved later when/if the drug is approved. All in all, 
Chorus accelerates the process (see figure 4.3).  
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Figure 4.3 Chorus’s Early-Stage Development (Bonabeau et al. 2008) elaborated by the 
authors 
 
In order not to let any capacity slip away, Chorus uses external experts as well in its research, 
making it an Open Innovation approach. These experts take care of experimental design and 
drug delivery, and there are also external vendors who provide manufacturing and toxicology 
for instance, which give the Chorus’s staff the possibility to focus on the evidences found in 
current trials (Bonabeau et al. 2008).  
 
There are a couple of examples that show the effectiveness of Chorus: the molecule 
compounds X32 and 4AB (Bonabeau et al. 2008). X32 was a molecule for treating psychosis 
that had not shown enough effectiveness. Lilly worked with it for five years and without a 
definitive result, it passed in on to Chorus. It took Chorus seven months to determine that the 
drug had no sufficient effect and it was cancelled. 4AB was a molecule for neurological 
disorders that had shown signs of affecting the vision. Chorus was able to dismiss that 
concern and the molecule was sent back to development. These are good examples of what 
Chorus was created for; reduce uncertainty quickly and cheaply.  
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Longman (2007) points out that the Chorus approach is not suitable for all types of drugs. It 
does not work well with molecules that demand more extensive work or novel compounds 
where the biomarkers are hard to predict. There is also a concern that problems can occur 
when an asset is moved between Lilly’s R&D department and Chorus due to operations 
within different expectation levels.  
4.3.3 FIPNet 
FIPNet stands for Fully Integrated Pharmaceutical Network and was the next step after 
FIPCO – Fully Integrated Pharmaceutical Company, which it had positioned itself as until 
2006. Lilly had understood that not all activities took place within the company and this term 
was a better fit (Schwartz & Huff, 2010). A network with other companies was built in order 
to let Lilly take part of technology and make it easier for collaborations. The companies in the 
network could collaborate with each other as well, which later could lead to benefits for Lilly 
due to its position as creator of the network. One example shows two companies that found 
each other through the network and then developed a service that benefited Lilly, and this was 
exactly the reason why this network was created (Schwartz & Huff, 2010).  
 
Sidney Taurel, Chairman of Lilly between 1999 and 2008, said in 2008 that he believed Lilly 
to be a pioneer within this area in the pharmaceutical industry because a high percentage of 
compounds are created outside the company as well as the fact that Chorus has been able to 
attract a large number of external scientists while at the same time decrease time and reduce 
costs (Lilly, 2012b). Lilly has found a third way apart from continuing the development under 
high financial risk or abandon it and sell it off when finding a promising discovery, namely to 
use firms in China and India who are willing to share the risk. In exchange these firms are 
offered payments and royalties when a successful molecule is invented as well as increased 
skills to their own employees while Lilly receives the IP rights. 
 
Sidney Taurel further believes that Lilly can benefit from the fact that high populous countries 
like India and China are producing an increasing amount of highly educated individuals. 
These countries still lack experience but an increasing number expatriates with that 
experience are returning and there Lilly has found opportunities to spread its development of 
FIPNet (Lilly, 2012b). 
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Schwartz and Huff (2010) concludes that FIPNet still is a relatively new initiative and that 
this network strategy might not be the final step for all companies. However, Lilly is a 
company that during the last 15 years has found an Open Innovation model that has shown to 
increase value. 
4.3.4 Open Innovation Drug Discovery 
Due to a number of challenges facing the pharmaceutical industry such as patent expirations 
and increasing restrictions as well as the ageing population and the rise in demand from 
emerging countries, pharmaceutical companies face extraordinary pressure (Lilly, 2012c). To 
deal with this pressure, new and different approaches are needed. Lilly founded InnoCentive 
as mentioned above and it recently started two new initiatives; a phenotypic drug discovery 
initiative called PD2 in 2009, and a target drug discovery initiative called TargetD2 in 2011. 
These two approaches are very complex, but they basically give opportunities for external 
scientists to use Lilly’s testing modules. These modules make it possible for the external 
scientists to identify biological activity of interest in order to formulate hypotheses in that 
field (Lilly, 2012d). 
 
As stated above, these two different approaches are very complex to understand, but the 
important aspects to understand in a business oriented way are the advantages that come with 
these approaches. Lilly uses research universities and institutes to get hold of test molecules 
that are used in the research process. These test molecules are then available for the external 
scientists to evaluate and will hopefully lead to breakthroughs (Lilly, 2012c). The PD2 and 
TargetD2 initiatives include testing modules where the external scientists can test their 
hypotheses (Lilly, 2012e). In this case, the external investigator/scientist will keep the IP right 
to his or her molecule solution. The goal is to receive thoughtfully considered hypotheses 
rather than a high quantity of submissions, and Lilly provides research tools to make it easier 
for these investigators’ experimentation. After the evaluation is completed, Lilly holds the 
right to negotiate first with scientists that come up with promising discoveries (Lilly, 2012e). 
 
To begin, the external investigator needs to sign up and accept a Material Transfer Agreement 
to become a member of the Open Innovation Drug Discovery platform. The investigator will 
then receive information about the process, how to submit compounds of molecules and what 
Lilly requires. If the compound models submitted are of sufficient quality, the investigator 
will move to the next step where he or she will be able to submit a physical sample (a more 
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detailed description of how the compounds are being evaluated is shown in figure 4.6). If 
Lilly too, finds the compound to be promising, Lilly and the investigator will proceed to 
negotiations about how to continue. Since the investigator will keep the patent, the 
negotiations will include discussions how they both can leverage on the discovery, i.e. 
through licensing or collaboration, but the investigator is free to leave with the patent as an 
option as well which raises questions how Lilly avoids that scenario (Lilly, 2012c).  
 
 
Figure 4.4 Open Innovation Drug Discovery Evaluation Cycle (Lilly, 2012f) elaborated by 
the authors 
 
The PD2 panel focuses on endocrinology and oncology diseases such as diabetes and cancer 
(Lilly, 2012c). The modules are further broken down into different compounds of molecules 
within these diseases and are used as starting points for external scientists and drug discovery. 
The TargetD2 panel works within the same branches in medicine as the PD2 panel and 
additionally with cardiovascular and neuroscience. It is important to bear in mind that these 
compounds of molecules being investigated and examined within these panels are rather 
complex and the important aspect here is what the Open Innovation process looks like due to 
the purpose of this thesis. 
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Lilly also has a special initiative towards the fight against tuberculosis (TBC) within the Open 
Innovation Drug Discovery initiative. The programme is called The Lilly TB Drug Discovery 
Initiative (TBDDI) and aims to accelerate the early-stage drug development and find 
tomorrow’s drug to fight the disease (Lilly, 2012g). It is a non-for-profit public-private 
partnership and gives the opportunity to the external investigators involved in the Open 
Innovation drug discovery to contribute to this initiative (Lilly, 2012c). Compounds submitted 
to the PD2 panel or the TargetD2 panel will automatically be sent to the Lilly TBDDI for 
consideration.  
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5. Analysis 
The fifth chapter provides an analysis of the case studies from the perspective of the 
theoretical framework and the empirical results. A discussion of reasons for the results will 
also be presented.  
5.1 Incentives for Open Innovation 
As stated by Chesbrough (2003), companies go outside their own walls to reach more 
qualified scientists and better ideas, and due to the cutbacks in the global economy all 
businesses and industries have had to reconsider their business models in order to maintain 
profit levels. Globalization and fiercer competition on the market have forced companies into 
working more efficiently with R&D in order to increase the number of innovations presented 
to the market. Furthermore, a decrease in productivity can be seen in the pharmaceutical 
industry today. R&D costs still need to be covered, and in order to do that there is no room in 
investing in development of drugs that are in low demand or in demand of people with low 
purchasing power. Open Innovation is something that could change this and solve the 
problem of pharmaceutical companies only investing in blockbuster drugs. Today, about one 
out of three drugs covers its own costs and generates profit, but before a drug gets launched to 
the market roughly 30 projects need to be invested in, which implies a success rate of about 3 
per cent. This means that when looking at the costs of one drug, not only does one have to 
calculate the drug’s proper costs, but also include the costs of failed projects. These costs need 
to be compounded and seen as the total costs that need to be covered by the sales. In addition, 
which has also been discussed earlier, the lead-time for a drug to reach the market is 
becoming longer and longer due to an increased demand for documentations. The effective 
lifetime of a patent in the pharmaceutical industry therefore decreases and furthermore, 
generic drugs are taking over earlier than before which creates additional difficulties of 
covering R&D costs. The role of Open Innovation and increased collaborations could help the 
innovation processes by decreasing the lead times and costs of R&D. 
 
For many diseases where there is no monetary profit to be made, such as malaria and TBC, 
collaborations and Open Innovation is a way for society and for pharmaceutical companies to 
reach out to these diseases without having to bare all costs alone. The R&D costs are too high 
for one company to take on solely, but together in a partnership with other companies and 
institutions, investment in remedies for these diseases is feasible.  
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Even though the investments in R&D in the pharmaceutical industry have increased, the 
number of successful products has stayed the same for the last 20-30 years. Companies know 
that changes are necessary in order to be more competitive and Lilly is in the forefront of 
finding new ways. Lilly wanted to find other ways to solve more problems, to be more 
efficient in its drug development and to be able to leverage on others’ capabilities. Lilly found 
the motivation and was able to transform them into goals, which it was later capable of 
reaching in many aspects when looking at the results.  
 
The incentive for InnoCentive was to reach more scientists and solve more problems, which it 
was able to do. Lilly started Chorus to be more effective in its early-stage drug development 
and results show it has been. FIPNet and Open Innovation Drug Discovery are still new 
projects, but the intention illustrates Lilly’s constant search of finding new ways and 
implementing them. 
5.2 Searching for Open Innovation 
AstraZeneca has realized that, in order for the company to continue on as one of the world’s 
biggest pharmaceutical companies, it needs external innovations in more ways than the 
company’s traditional collaborations with academia and smaller pharmaceutical or biotech 
companies. The company has a goal of having at least 40 per cent of its innovation portfolio 
licensed in from external sources and it has commenced with more complex collaborations 
such as PPP and pre-competitive collaborations in order to further access innovations from 
other prominent researchers and companies, i.e. the best talented. AstraZeneca is still one of 
the world’s biggest companies within the industry, however, there is an openness within the 
company of moving further towards Open Innovation processes, which is an essential mindset 
in order to stay competitive in today’s business environment. 
 
AstraZeneca has, in general, three ways of looking for external knowledge; 1) Researchers 
bring their own network of important people and talents to the company. 2) Business 
Development group focusing on different diseases that scouts the global market for new 
innovations and solutions to problems and sees how the company itself could benefit from 
these new, external innovations. Another part of the Business Development group is the one 
who is focusing on other pharmaceutical companies to see what is in the competitors’ 
pipelines. 3) Researchers at AstraZeneca are continuously taking part of new research within 
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their field by reading recently published articles, going to seminars etc. As a consequence, 
AstraZeneca’s internal researchers are introduced to new ideas and innovations. These 
approaches illustrate the willingness to integrate external knowledge in the company’s 
business model. 
 
Lilly is a pioneer in Open Innovation within the pharmaceutical industry and InnoCentive and 
FIPNet are two examples of this. R&D in the pharmaceutical industry is crucial but also 
expensive and time consuming, and Lilly’s approaches of finding new ways have put it in its 
market leading position. Lilly started with InnoCentive where it tried to solve difficult 
problems and was able to reach its goal with a higher rate of solved problems. The project 
proves that searching will lead to finding and that outside parties can play significant roles in 
this industry.  
 
The way Lilly has been able to find other companies or other scientists through establishing a 
network (FIPNet) or starting up an Internet forum (InnoCentive) clearly illustrates the 
advantages of having a good reputation. Lilly has built it up over the years by inventing well-
known pharmaceuticals and has been capable of bringing companies into the network and 
attract scientists to its InnoCentive platform. The success can further be related to Fetterhoff 
and Volkel’s (2006) ideas on how to create value through seeking, evaluating, recruiting, 
capture value and continue to extract value. In Open drug discovery Lilly is able to recruit and 
capture value by having the rights to negotiate first with scientists who come up with 
molecule solutions. The seeking and evaluating processes of InnoCentive are other examples 
that demonstrate its ability to search and grasp opportunities. 
5.3 Openness and collaborations 
Based on interviews with influential people at AstraZeneca, the perception is such that the 
company still, regardless investments in PPP and pre-competitive collaborations, keeps a 
traditional mindset of wanting all the best people to work for the company. The difference 
between Open Innovation and AstraZeneca’s definition is that the traditional/closed model’s 
appraisal of internal innovations still lingers at the backbone of AstraZeneca, and the 
company explains that it is looking for the best talents and the best scientists in the industry. 
However, it has been shown that AstraZeneca is opening up innovation processes by looking 
for external knowledge to a larger extent than earlier, and the company puts much effort into 
looking for external knowledge to further develop in-house (AstraZeneca, 2012f). 
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As seen in the case study of Lilly, the company is trying to be open and has tried a number of 
new approaches in the last decade. It is interesting to see that Lilly is not trying to search for 
single companies to work with; instead it tries to build networks and incorporate ideas from 
individual scientists. Collaborations with companies is not a new phenomenon, which Lilly is 
aware of and has chosen to try other ways to improve R&D with the purpose of becoming 
more profitable.  
 
In the last years, Lilly has started to look Far East (e.g. China and India) in its attempts to 
expand its Open Innovation approach. There are many small pharmaceutical firms in these 
countries where scientists, who have been working in the Western world for prominent 
pharmaceutical companies, are bringing knowledge back to Asia. In its FIPNet approach, 
Lilly has been working with these companies and the results show that there are resources in 
those countries that can be tapped by Big Pharma. Lilly also knows that these companies want 
to gain further knowledge from western companies, which is something that Lilly can offer 
and in return receive IP rights. Both parties understand that this allows for a win-win situation 
and these relationships could give Lilly an advantage over other Big Pharma unless these 
competitors take the same path. 
 
There are dangers of being too open as well, and these dangers are related to IP rights in 
particular. However, because of the importance of patents in this industry, companies keep 
them well protected. Openness is more likely to create opportunities to share technology and 
other services as the case of FIPNet, and by being the creator of such a vast network; Lilly has 
the possibility to leverage on collaborations taking place.  
 
AstraZeneca talks about relationships and collaborations in a way it always has to a large 
extent. Lilly on the other hand, has put much effort the last decade to find alternative ways to 
innovate, and future outcomes of these projects will tell if Lilly will become more successful. 
However, it is interesting to see that AstraZeneca and Lilly perceive Open Innovation in two, 
more or less, different ways. 
5.4 Crowdsourcing 
As mentioned, AstraZeneca is a traditional company in the pharmaceutical industry in terms 
of innovation and when it comes to crowdsourcing as new grounds for exploring new 
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innovations and initiatives, AstraZeneca has yet to learn more. Today, AstraZeneca is not 
employing any specific strategy in order to take advantage of crowd knowledge. Dr. Ekblom, 
however, states that crowdsourcing is something that the company would like to become 
better at as it sees many of its competitors going towards a more Open Innovation process that 
includes crowdsourcing and crowd knowledge. There are many successful examples of 
crowdsourcing, both within the pharmaceutical industry and in other industries, which have 
affected the company’s view on openness towards crowd knowledge. At AstraZeneca, 
collaborations take place to a great extent, yet the pharmaceutical industry is much more 
complex and requires much more expert knowledge than e.g. the IT industry, where it is 
possible for anyone to come up with new ideas, programs and solutions at home. This, 
naturally, is not the case in the pharmaceutical sector where the usage of crowd knowledge is 
more difficult to adopt.  
 
The approach of using the crowd’s knowledge is, however, certainly something that Lilly is 
aware of. The company started InnoCentive, which has made it possible to reach a large 
number of independent scientists regardless of their geographical location who have been able 
to come up with solutions for Lilly’s problems. As well as crowd creation, crowd wisdom 
undoubtedly plays a big role here, and results show that these researchers have solved many 
problems that could not be solved in-house.  
 
InnoCentive makes it possible for external parties to understand the problems, which Thomke 
and von Hippel (2002) point out as important. The platform is user-friendly due to skilled 
employees who are able to explain problems to the solvers and this makes the problems 
available to a greater number of people (140,000 users all over the world). In addition it is 
simple to understand the rules when engaging; one either solves the problem and receives a 
reward, or fails and is left without any compensation. Even though this has been criticized, the 
reward certainly motivates people to try to solve the problems. 
 
Today, InnoCentive is an independent company, yet Lilly still uses it and the success rate 
when referring to posted problems shows that there are problems within a pharmaceutical 
company that external sources are able to solve. Everything is not about developing 
complicated molecule compounds that demand qualified scientists, and that is something that 
Lilly has taken advantage of. Crowdsourcing is a relatively new concept, and this is possibly 
the first of many similar attempts within this area in the pharmaceutical industry. 
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5.5 The managing of Intellectual Property rights 
The pharmaceutical industry is an industry where IP rights play an important role for the 
survival of the involved companies. When it comes to AstraZeneca and how the company 
sees in the case of Open Innovation, it can be said that many of the company’s collaborations 
are executed in the open space. This means that in projects like Innovative Medicines 
Initiative (IMI) and Medicines for Malaria Venture (MMV) where the company collaborates 
with both other companies and institutions such as the EU (the Commission) or the UN, 
innovations become open i.e. all data is published. This in turn indicates that none of the 
parties involved is able to apply for the patent of the innovation. The same goes for pre-
competitive collaborations where governments or other non-profit organizations are involved. 
According to Dr. Ekblom, there are two reasons why AstraZeneca engages in projects where 
no patent can be received: 1) To engage in projects such as IMI or MMV is rather considered 
as a part of the company’s CSR than being a source of income. 2) For pre-competitive 
collaborations it is beneficial for AstraZeneca, as well as for other pharmaceutical companies, 
that the biomarkers developed within these collaborations become published and broadly 
accepted since this leads to decreased lead times for the development of a drug. However, in 
pre-competitive/competitive collaborations it is easily understood that issues of IP rights will 
emerge. These issues prolong the innovation process and the companies involved risk high 
costs in time lost and in legal costs. These issues are normally solved with the creation of a 
new enterprise that will be the juridical owner of the patent created. 
 
Lilly tries to clarify ownership rights before starting up a project or engaging in co-operations. 
Lilly’s first Open Innovation project, InnoCentive, solved the issue through a contract stating 
that the patent belonged to the seeking company. All external scientists trying to solve 
problems have to sign this contract before having the possibility the view a problem. Lilly 
knows that the patent is crucial in this industry and individual solvers are satisfied with a cash 
reward or just the satisfaction of solving a complicated problem. 
 
Chorus is not a typical Open Innovation approach that tries to reach out to external parties for 
innovation that leads to patents. External scientists contribute with knowledge around the 
molecules such as toxicology and experimental design while Chorus’s employees focus on 
trials of portfolios of molecules. The findings are later sent back to Lilly’s R&D department 
for further development. Chorus basically uses external knowledge to speed up the 
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development process, but since core operations are kept within the firm and final products are 
developed in-house, there are no issues regarding IP rights. 
 
The recently established FIPNet fuels this issue since it makes these questions more 
complicated to solve. Companies set out collaborations in a number of different ways and it is 
hard to understand how contracts are written and detailed. It is most likely that these 
companies work out patent issues between themselves, while Lilly is able to take part of 
technology, services or other related features. When it comes to collaborations where Lilly is 
directly involved, it has been able to get hold of patents while the co-operating firm can take 
advantage of the knowledge learned from Lilly as well as royalties and cash rewards. This is 
the case when a co-operation has led to a successful drug as in the case with inexperienced 
Asian pharmaceutical companies. 
 
In Lilly’s new approach, Open Innovation Drug discovery, the company has chosen another 
way of managing patents. The scientist that comes up with a molecule discovery or innovation 
when using Lilly’s testing modules will receive the IP rights and is free to leave with it. The 
goal for Lilly is to pursue this person with an offer they both can profit from and establish 
some kind of collaboration. As a result of having the first negotiation rights, Lilly has a good 
possibility to establish a relationship, and in addition, the company understands that it has the 
financial and operational resources to develop this molecule. The scientist is also aware of the 
parties’ different capabilities. The risk is that the scientist turns down the offer and turns to 
other companies, but since everything is developed by using Lilly’s equipment, other 
companies may be uncertain of the molecule’s possible use. In addition, if Lilly finds the 
molecule to be highly promising, it will certainly propose an offer that is hard to refuse. 
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6. Conclusion 
In this chapter the findings of the empirical study will be concluded, furthermore 
recommendations for future research on the subject will also be presented. 
 
To refer back to the research questions for this thesis; how is Open Innovation conducted in 
companies (AstraZeneca and Lilly) in the pharmaceutical industry? What are the incentives 
for these companies to engage in Open Innovation? And, are there any difficulties concerning 
IP rights when engaging in Open Innovation? This thesis has illustrated the innovation 
processes of two global companies in the pharmaceutical industry, AstraZeneca and Lilly, and 
explained what strategies these two companies employ in order to deal with the current 
situation of increased competition, increased costs and decreasing incomes. To illustrate this, 
the Closed and Open Innovation paradigms have been presented as well as the importance of 
IP rights in the pharmaceutical industry. Furthermore, the theory of the product lifecycle has 
been explained in order to illustrate the increasing need for new innovations. 
 
Globalization has increased competition by increasing the number of educated and talented 
people and scientists, and it has also decreased product lifecycles due to the number of 
competing firms on the global market. This thesis concludes that there is a need for 
companies in the pharmaceutical industry today to be close to breakthrough science in order 
to stay competitive. AstraZeneca is doing this by being physically located close to academia, 
engaging further in collaborations such as IMI and MMV and is currently restructuring its 
activities in Sweden in order to increase the company’s flexibility, and Lilly has initiated 
several digital platforms such as InnoCentive and Open Innovation Drug Discovery. It also 
concludes that the characteristics of smaller biotech firms and larger pharmaceutical 
companies, such as AstraZeneca and Lilly, can complement each other in order to decrease 
lead times and R&D costs.  
 
In order to illustrate the need for change in the industry, this thesis concludes that Open 
Innovation has a role in achieving companies’ goals of enable faster and cheaper R&D. Lilly 
has initiated a number of Open Innovation projects the last decade that have been successful. 
AstraZeneca is in the preface of engaging in Open Innovation by commencing projects such 
as IMI and other pre-competitive collaborations that have led to faster and cheaper 
development of biomarkers. 
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Considering the issue of IP rights, one part of the purpose of this thesis has been to investigate 
whether this implies any problems or complications when engaging in Open Innovation 
projects. The findings show that IP rights are essential, especially for companies in the 
pharmaceutical industry, and it is clear that the examined companies realize this. It can be 
concluded that in general, both AstraZeneca and Lilly have legal experts that assists in 
developing and setting up clear and well defined contracts before any collaboration begins, 
regardless the nature of the collaboration. However, the party to receive the patent can vary 
and depends on the project, and if an innovation has been created in a fully transparent, open 
space it is hard to create any ownership rights at all. In addition, it has been shown that the 
two companies are engaging in projects where the gain of IP rights is not the most important 
factor, which implies that there is an ongoing change considering the perception of patents.   
 
AstraZeneca and Lilly do not adopt the same approach towards Open Innovation. 
AstraZeneca still operates in a more traditional way of collaborating and is a little more 
concerned of opening up for alternative ways. Lilly has been, and still is, a pioneer who has 
been involved in or initiated a number of Open Innovation projects. AstraZeneca has lately 
started to look for new ways and time will tell if the company will be able to come up with 
successful approaches. 
6.1 Recommendations 
AstraZeneca and Lilly are only two of many Big Pharmas, and even though they provide 
examples of how Open Innovation can be performed and why companies are trying to attract 
external knowledge they do not represent a general approach to Open Innovation in the 
pharmaceutical industry. Further there is a difference between these two companies in terms 
of how they perceive Open Innovation, which makes it even more difficult to draw general 
conclusions that apply to the whole industry and might indicate that there could be, in 
addition, other alternative ways Big Pharmas approach this subject. Therefore it would be 
interesting for future research to investigate additional companies in the pharmaceutical 
industry in order to provide a more generalized overview. 
 
What can be said after examining these two companies as well as having discussions with 
researchers and professionals within the subject is that there is a general perception that Open 
Innovation will play a big role in the future within the pharmaceutical industry. This thesis 
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gives an idea of where two of the largest pharmaceutical companies stand in this relatively 
new area, and future research should focus on trying to create an overview of the whole 
industry. In that way, patterns and dissimilarities can be discovered and provide a deeper 
understanding of Open Innovation, and why and how companies are trying to obtain and 
attract external knowledge. 
 
In addition, the changes and the restructuring of the pharmaceutical industry is something that 
has only been mentioned shallowly in this thesis, however, it is an essential aspect that 
deserves further attention. 
 
Finally, future research should try to link Open Innovation within the pharmaceutical industry 
with other industries in order to find out where potential collaborations can be performed as 
well as where pitfalls exist.  
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7. Appendix 
Appendix 1. 
Interview template 
 
Interview for the bachelor thesis ”The Role of Open Innovation -focus on the Pharmaceutical 
Industry”, School of Business, Economics and Law, University of Gothenburg. 
 
Interviewees: Anders Ekblom, CEO AstraZeneca Sweden, AstraZeneca, Södertälje. 
Mats Sundgren, Principal Scientist within Global Clinical Development, AstraZeneca R&D, 
Mölndal. 
 
1. AstraZeneca’s definition of Open Innovation. 
 
- What are the advantages of Open Innovation to AstraZeneca? 
- What are the disadvantages of Open Innovation to AstraZeneca? 
2. External knowledge. 
 
How does AstraZeneca proceed in finding potential partners, collaborations and 
external sources? Is the company actively searching? 
- How are these partners and external sources evaluated? What does the 
organization look like? 
- Concrete examples? 
 
3. Crowdsourcing. 
What does AstraZeneca think about the usage of ”crowd-knowledge”, i.e. crowdsourcing, in 
order to solve problems and create innovations in the pharmaceutical industry? Examples of 
crowdsourcing as open platforms are www.patientslikeme.com and Lilly’s InnoCentive. 
4. The future. 
What do You see in the future for Open Innovation within the pharmaceutical industry? 
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